# Trade Mark Journal No.2026/011 13 March 2026

## WO0000001904976 (5,42)

Office of origin: United States of America

Date of International Registration:30 January 2026
Date of designation in the UK: 30 January 2026

International priority date claimed: 1 August 2025 (United States of America) (99314648)

Class 5
  Pharmaceutical preparations for the treatment of myeloproliferative neoplasms and other hematologic diseases.
Class 42
  Pharmaceutical research in the field of hematology and oncology.

JLSA Therapeutics Inc.

Representative: Michael Graif, 7 Times Square, New York NY 10036, UNITED STATES OF AMERICA